Faron Pharmaceuticals Oy Statistics
Faron Pharmaceuticals Oy (4FR) Stock Statistics & Valuation Metrics
Total Valuation
Faron Pharmaceuticals Oy has a market cap or net worth of EUR 73.04M. The enterprise value is EUR 60.49M.
- Market Cap
- EUR 73.04M
- Enterprise Value
- EUR 60.49M
Share Statistics
Faron Pharmaceuticals Oy has 227,881,320 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 227,881,320
- Owned by Insiders
- 2.04%
- Owned by Institutions
- ―
Financial Efficiency
Faron Pharmaceuticals Oy’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
- Return on Equity (ROE)
- ―
- Return on Assets (ROA)
- ―
- Return on Invested Capital (ROIC)
- ―
- Return on Capital Employed (ROCE)
- ―
- Revenue Per Employee
- ―
- Profits Per Employee
- -371.76K
- Employee Count
- 25
- Asset Turnover
- ―
- Inventory Turnover
- ―
Income Statement
In the last 12 months, Faron Pharmaceuticals Oy had revenue of ― and earned -9.29M in profits. Earnings per share was ―.
- Revenue
- ―
- Gross Profit
- 1.15M
- Operating Income
- -8.86M
- Pretax Income
- ―
- Net Income
- -9.29M
- EBITDA
- -9.03M
- Earnings Per Share (EPS)
- ―
Stock Price Statistics
- Beta
- 0.04
- 52-Week Price Change
- -84.03%
- 50-Day Moving Average
- 0.39
- 200-Day Moving Average
- 0.48
- Relative Strength Index (RSI)
- 35.87
- Average Volume (3m)
- 2,561
Important Dates
Faron Pharmaceuticals Oy upcoming earnings date is Mar 19, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 26, 2026
- Next Earnings Date
- Mar 19, 2027
- Ex-Dividend Date
- ―
Balance Sheet
Faron Pharmaceuticals Oy has ― in cash and marketable securities with EUR 2.36M in debt, giving a net cash position of ― billion.
- Cash & Marketable Securities
- ―
- Total Debt
- EUR 2.36M
- Net Cash
- ―
- Net Cash Per Share
- ―
- Tangible Book Value Per Share
- ―
Analyst Forecast
The average price target for Faron Pharmaceuticals Oy is EUR 11.96, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 11.96
- Price Target Upside
- 3416.48% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 55.48%

